Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases
Background : Telomerase activity ( TA ) is considered as the biomarker for cardiovascular aging and cardiovascular diseases ( CVDs ) . Recent studies suggest a link between statins and telomere biology that may be explained by anti-inflammatory actions of statins and their positive effect on TA . Until now , this effect has not been investigated in prospect i ve r and omized studies . We hypothesized that 12 months of atorvastatin therapy increased TA in peripheral blood mononuclear cells . Methods : In a r and omized , placebo-controlled study 100 hypercholesterolemic patients , aged 35–75 years , free of known CVDs and diabetes mellitus type 2 received 20 mg of atorvastatin daily or placebo for 12 months .  TA was measured by quantitative polymerase chain reaction . Results : At study end , 82 patients had sufficient peripheral blood mononuclear cells needed for longitudinal analysis . TA expressed as natural logarithms changed from 0.46 ± 0.05 to 0.68 ± 0.06 ( p = 0.004 ) in the atorvastatin group and from 0.67 ± 0.06 to 0.60 ± 0.07 ( p = 0.477 ) in the control group . In multiple regression analysis , atorvastatin therapy was the only independent predictor ( p = 0.05 ) of the changes in TA independently of markers of chronic inflammation and oxidative stress . Atorvastatin therapy was associated with increases in interleukin-6 within the normal range and a tendency toward reduction in blood urea . Conclusion : These initial observations suggest atorvastatin can act as telomerase activator and potentially as effective geroprotector . Trial registration : The trial was registered in IS RCT N registry IS RCT N55050065
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .